Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1375480 | Bioorganic & Medicinal Chemistry Letters | 2005 | 7 Pages |
Novel 5-HT1 autoreceptor ligands based on the N-4-aryl-piperazinyl-N′-ethyl-5,6,7,8-tetrahydropyrido[4′, 3′:4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT1A and 5-HT1B receptors. Strategies for the development of dual 5-HT1A and 5-HT1B antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT1A and the 5-HT1B receptors and was characterized further with respect to selectivity, electrically stimulated [3H]5-HT release and in vivo efficacy.
Graphical abstractNovel 5-HT1 autoreceptor ligands based on the tetrahydropyridothieno-pyrimidinone core are described. Strategies for the development of dual antagonists for the 5-HT1A and 5-HT1B receptors based on 1 and 2 as leads are discussed. Compounds displaying high affinities and an antagonist mode of action were examined for selectivity and characterized in additional assays.Figure optionsDownload full-size imageDownload as PowerPoint slide